返回 
加入收藏
紫杉醇联合顺铂新辅助化疗用于进展期食管癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 紫杉醇联合顺铂新辅助化疗用于进展期食管癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察紫杉醇联合顺铂新辅助化疗用于进展期食管癌的疗效和安全性。方法：100例拟行手术治疗的进展期食管癌患者随机分为观察组（50例）和对照组（50例）。观察组患者术前给予紫杉醇注射液175 mg/m2，d1，静脉滴注+顺铂注射液20 mg/m2，d1-5，静脉滴注；5 d为1个疗程，共2个疗程，并在常规手术治疗后根据疗效以调整用药方案继续化疗2个疗程；对照组患者术后给予紫杉醇注射液（用法用量同观察组）+顺铂注射液（用法用量同观察组），5 d为1个疗程，共4个疗程。观察两组患者的临床疗效，治疗前后高迁移率蛋白B1（HMGB1）、癌胚抗原（CEA）及鳞状上皮细胞癌抗原（SCC-Ag）水平，毒副反应发生率、术后并发症发生率和术后1、3、5年生存率。结果：观察组患者客观缓解率显著高于对照组，观察组患者HMGB1、CEA、Scc-Ag及对照组患者HMGB1、CEA水平均显著低于同组治疗前，且观察组HMGB1、SCC-Ag低于对照组，差异均有统计学意义（P＜0.05）；两组患者疾病控制率、毒副反应发生率、术后并发症发生率和1、3、5年生存率及中位生存时间比较，差异均无统计学意义（P＞0.05）。结论：紫杉醇联合顺铂新辅助化疗能显著提高进展期食管癌患者的疗效，降低肿瘤标志物水平，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy of taxol combined with cisplatin neoadjuvant chemotherapy in the treatment of esophageal cancer and effects on serum tumor markers in patients with esophageal cancer. METHODS： 100 patients with esophageal cancer were randomly divided into control group（50 cases） and observation group（50 cases）. Observation group was given taxol+Cisplatin injection （TP） neoadjuvant chemotherapy， given 175 mg/m2 taxol by intravenous infusion， d1-5. And every 5 d was a treatment course， the regimen was adjusted based on patients’ efficacy； control group was given conventional surgery and TP after surgery， the same usage and dosage as observation group， it lasted for 4 courses. Clinical efficacy，high mobility protein B1（HMGB1）， carcinoembryonic antigen （CEA） and squamous cell carcinoma antigen （SCC-Ag） level in 2 groups before and after treatment were observed， objective response rate， disease control rate， the incidence of toxicity and severe toxicity， incidence of postoperative complications and survival rate of postoperative 1，3 and 5 years were recorded. RESULTS： After treatment， objective response rate in observation group was significantly higher than control group， HMGB1， CEA and SCC-Ag levels were significantly lower than before and control group， HMGB1 and CEA levels in control group were significantly lower than before， the differences were statistically significant （P＜0.05）； there were no significant differences in the disease control rate， chemotherapy-related toxicity， severe toxicity， incidence of postoperative complications， survival rate of postoperative 1， 3 and 5 years and the median survival time between 2 groups（P＞0.05）. CONCLUSIONS： Taxol combined with cisplatin neoadjuvant chemotherapy can significantly improve the efficacy of patients with esophageal cancer and reduce the levels of cancer-related indicators， with good safety. |
| 期刊： | 2016年第27卷第18期 |
| 作者： | 吕会来，张丽，温士旺，张月峰，李勇，田子强 |
| AUTHORS： | LYU Huilai，ZHANG Li，WEN Shiwang，ZHANG Yuefeng，LI Yong，TIAN Ziqiang |
| 关键字： | 食管癌；紫杉醇；顺铂；新辅助化疗；肿瘤标记物；疗效；安全性 |
| KEYWORDS： | Esophageal carcinoma； Taxol； Cisplatin； Neoadjuvant chemotherapy； Tumor markers； Efficacy； safety |
| 阅读数： | 310 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
